- Move reflects increasing investment in AI as driving force
for innovation and productivity.
- Company will host Innovation Summit in December focused on
AI in R&D.
WASHINGTON, June 5, 2024
/PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science
and technology innovator, today announced the creation of the new
role of Chief Data & Artificial Intelligence (AI) Officer and
the appointment of Dr. Martin Stumpe
to the role.
Jose-Carlos Gutierrez-Ramos,
Senior Vice President and Chief Science Officer,
Danaher, said: "We are delighted to welcome Dr. Stumpe to
our team. His extensive experience in leveraging AI to drive
scientific and operational progress will be critical in further
supporting Danaher's AI and data strategy to advance
innovation."
Dr. Stumpe most recently served as Chief of AI at Tempus, where
he spearheaded AI initiatives aiming to make precision medicine a
reality. Prior to Tempus, he founded the Cancer Pathology project
at Google – which aimed to enhance the accuracy of cancer detection
and grading using AI techniques – and was part of the Kepler team
at NASA's Ames Research Center. Dr. Stumpe holds a Ph.D. in
Computational & Theoretical Physics from the Max Planck
Institute for Biophysical Chemistry in Germany. He will report to Dr.
Gutierrez-Ramos.
Danaher is increasingly focusing on AI through inorganic
investment, strengthening internal capabilities, and collaborating
with leading academic institutions. In December, the company will
host the third annual Danaher Summit, bringing together visionary
leaders and innovators to discuss AI's potential impact on
biopharmaceutical research and development.
ABOUT DANAHER
Danaher is a leading global life sciences and diagnostics
innovator, committed to accelerating the power of science and
technology to improve human health. Our businesses partner closely
with customers to solve many of the most important health
challenges impacting patients around the world. Danaher's advanced
science and technology – and proven ability to innovate – help
enable faster, more accurate diagnoses and help reduce the time and
cost needed to sustainably discover, develop and deliver
life-changing therapies. Focused on scientific excellence,
innovation and continuous improvement, our approximately 63,000
associates worldwide help ensure that Danaher is improving quality
of life for billions of people today, while setting the foundation
for a healthier, more sustainable tomorrow. Explore more
at www.danaher.com.
FORWARD-LOOKING STATEMENTS
Statements in this release that are not strictly historical,
including any statements regarding Danaher's AI and data strategy,
AI focus areas and any other events or developments that Danaher
believes or anticipates will or may occur in the future are
"forward-looking" statements within the meaning of the federal
securities laws. There are a number of important factors that could
cause actual results, developments and business decisions to differ
materially from those suggested or indicated by such
forward-looking statements and you should not place undue reliance
on any such forward-looking statements. These factors include,
among other things, the factors set forth in Danaher's SEC filings,
including our 2023 Annual Report on Form 10-K and Quarterly Report
on Form 10-Q for the first quarter of 2024. These forward-looking
statements speak only as of the date of this release and except to
the extent required by applicable law, Danaher does not assume any
obligation to update or revise any forward-looking statement,
whether as a result of new information, future events and
developments or otherwise.
View original
content:https://www.prnewswire.com/news-releases/danaher-appoints-martin-stumpe-to-new-role-of-chief-data--artificial-intelligence-officer-302164158.html
SOURCE Danaher Corporation